Featured Clinical Trial:

Prostate cancer (product/compound: Dasatinib; Docetaxel)

ClinicAid Locations: Southern California – Corona, Riverside

Status: Enrollment closed.

Condition: Prostate Cancer

Product Name/Compound: Dasatinib; Docetaxel

Full Study Title: A Randomized Double-Blind Phase III Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer

Study Summary: To determine whether survival can be prolonged in patients with castration-resistant prostate cancer who received dasatinib in addition to Docetaxel and prednison

Eligible Participants:

Inclusion (Eligible):

• Histologically diagnosed prostate cancer
• Evidence of metastatic disease
• Evidence of progression, by rising PSA, nodal/visceral disease, bone scan, or local recurrence
• Serum testosterone ≤50 ng/dL

Exclusion (Not Eligible):

• Symptomatic brain or leptomeningeal metastases
• Clinically significant cardiovascular disease
• Pleural or pericardial effusion
• Currently active second malignancy
• Uncontrolled intercurrent illness
• Prior cytotoxic chemotherapy, with the exception of estramustine

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT00744497

<< Back to all ClinicAid clinical trials